TY - JOUR
T1 - CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines
AU - Sicoli, Daniela
AU - Jiao, Xuanmao
AU - Ju, Xiaoming
AU - Velasco-Velazquez, Marco
AU - Ertel, Adam
AU - Addya, Sankar
AU - Li, Zhiping
AU - Andò, Sebastiano
AU - Fatatis, Alessandro
AU - Paudyal, Bishnuhari
AU - Cristofanilli, Massimo
AU - Thakur, Mathew L.
AU - Lisanti, Michael P.
AU - Pestell, Richard G.
N1 - Publisher Copyright:
© 2014 American Association for Cancer Research.
PY - 2014/12/1
Y1 - 2014/12/1
N2 - Src family kinases (SFK) integrate signal transduction for multiple receptors, regulating cellular proliferation, invasion, and metastasis in human cancer. Although Src is rarely mutated in human prostate cancer, SFK activity is increased in the majority of human prostate cancers. To determine the molecular mechanisms governing prostate cancer bone metastasis, FVB murine prostate epithelium was transduced with oncogenic v-Src. The prostate cancer cell lines metastasized in FVB mice to brain and bone. Gene expression profiling of the tumors identified activation of a CCR5 signaling module when the prostate epithelial cell lines were grown in vivo versus tissue cultures. The whole body, bone, and brain metastatic prostate cancer burden was reduced by oral CCR5 antagonist. Clinical trials of CCR5 inhibitors may warrant consideration in patients with CCR5 activation in their tumors.
AB - Src family kinases (SFK) integrate signal transduction for multiple receptors, regulating cellular proliferation, invasion, and metastasis in human cancer. Although Src is rarely mutated in human prostate cancer, SFK activity is increased in the majority of human prostate cancers. To determine the molecular mechanisms governing prostate cancer bone metastasis, FVB murine prostate epithelium was transduced with oncogenic v-Src. The prostate cancer cell lines metastasized in FVB mice to brain and bone. Gene expression profiling of the tumors identified activation of a CCR5 signaling module when the prostate epithelial cell lines were grown in vivo versus tissue cultures. The whole body, bone, and brain metastatic prostate cancer burden was reduced by oral CCR5 antagonist. Clinical trials of CCR5 inhibitors may warrant consideration in patients with CCR5 activation in their tumors.
UR - http://www.scopus.com/inward/record.url?scp=84918564403&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84918564403&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-14-0612
DO - 10.1158/0008-5472.CAN-14-0612
M3 - Article
C2 - 25452256
AN - SCOPUS:84918564403
VL - 74
SP - 7103
EP - 7114
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 23
ER -